<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"><channel><title>Biotech Tops The 'Most Bullish Conversations' And Breaks Out — Live Feed</title><link>https://www.live-feeds.com/feed/biotech-tops-the-most-bullish-conversations-and-breaks-out</link><atom:link xmlns:atom="http://www.w3.org/2005/Atom" href="https://www.live-feeds.com/feed/biotech-tops-the-most-bullish-conversations-and-breaks-out/rss.xml" rel="self" type="application/rss+xml"/><description>Continuously updated, source-cited coverage.</description>
<item><title>CG Oncology leads biotech surge after Phase 3 bladder cancer win</title><link>https://www.live-feeds.com/feed/biotech-tops-the-most-bullish-conversations-and-breaks-out</link><guid isPermaLink="false">https://www.live-feeds.com/feed/biotech-tops-the-most-bullish-conversations-and-breaks-out#u209891</guid><pubDate>Fri, 20 Nov 2026 06:21:49 +0000</pubDate><description>Biotech tops market bullishness rankings as CG Oncology&amp;#039;s shares surge 291% above IPO price following Phase 3 trial success for its bladder cancer immunotherapy. The treatment significantly reduced tumor recurrence risk, prompting the company to prepare expanded FDA discussions. Monday&amp;#039;s biotech session delivered two trial wins including CG&amp;#039;s result, offset by one trial miss and an FDA rejection elsewhere.Why it mattersCG Oncology&amp;#039;s Phase 3 victory validates its intravesical immunotherapy approach for non-muscle invasive bladder cancer, a space with high unmet need. The 291</description></item>
</channel></rss>